Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BLI-1300 Ointment for Perianal Crohn's Disease Pain
NCT01442363Phase 2Terminated
- Sponsor
- Braintree Laboratories
- Start
- Nov 2011
- Primary completion
- Oct 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of bli-1300 in Crohn's disease (3 arms), sponsored by Braintree Laboratories. Primary endpoint: Percentage of Perianal Pain Responders at 12 weeks. Started Nov 2011; status: terminated.
02
Drugs
bli-1300
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT01442363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01442363.